Superworth

TherapeuticsMD profit margin TXMD

Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.

Net margin, 12 months
−6.6%
Net margin on a year earlier
+11.3 pts
Peer median
9.2%

Over the twelve months to Jun 30, 2026, TherapeuticsMD kept −6.6% of its revenue as net profit.

The median for 3 large drugmakers of a similar size is 9.2%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−18.8%n/an/a
FY2024n/an/an/a
FY2023n/an/a100.0%
FY2022n/a1.7%n/a
FY2021n/an/a78.3%
FY2020n/an/a75.4%
FY2019n/an/a87.2%
FY2018n/an/a83.0%
FY2017n/an/a84.3%
FY2016n/an/a78.4%
FY2015n/an/a77.6%
FY2014n/an/a75.6%
FY2013n/an/a77.7%
FY2012n/an/a64.7%
FY2011n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−6.6%+11.3 ptsn/a
Q1 FY265.3%n/an/a
Q4 FY25−18.8%n/an/a
Q3 FY2510.8%n/an/a
Q2 FY25−17.9%n/an/a
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY2398.5%+141.6 pts59.9%

Against its peers

Companies in Drug Manufacturers - General nearest TherapeuticsMD's size, closest first, today.

CompanyProfit margin
TXMDTherapeuticsMD−6.6%
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics15.7%
LFVNLifevantage2.8%
Peer median9.2%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on TherapeuticsMD

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.